会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
    • 含氨基和羟基的生物活性剂的聚合物前药
    • US06180095B2
    • 2001-01-30
    • US09183557
    • 1998-10-30
    • Richard B. GreenwaldAnnapurna PendriYun H. Choe
    • Richard B. GreenwaldAnnapurna PendriYun H. Choe
    • A61K3121
    • A61K47/60
    • The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric prodrugs are preferably of the formula: wherein: L1 is a bifunctional linking moiety; G is H or where B is H, a leaving group, a residue of an amine-containing moiety, or a residue of a hydroxyl-containing moiety; Y1-4 are independently, O, S, or NR12; R1, R4, R9, R10, and R12, are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls; R2, R3, R5 and R6 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C1-6 alkoxy, phenoxy, C1-8 heteroalkyls, C1-8 heteroalkoxy, substituted C1-6 alkyls, C3-8 cycloalkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, halo-, nitro-, cyano-, carboxy-, C1-6 carboxyalkyls and C1-6 alkyl carbonyls; Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; (m), (r), (s), (t), (u) and (v) are independently zero or one; (p) is zero or a positive integer; and R11 is a substantially non-antigenic polymer. The first prodrug is generated when the polymeric portion of the double prodrug is cleaved and the parent molecule is generated rapidly thereafter in vivo, preferably as a result of 1,6 or 1,4 benzyl elimination-reaction. Methods of preparing the compounds and methods of treatment are also disclosed.
    • 本发明涉及含有基于聚合物的输送形式的双重前药。 这些聚合前药优选具有下式:其中:L1是双官能连接部分; G是H或其中B是H,离去基团,含胺部分的残基或含羟基部分的残基; Y1- 4独立地是O,S或NR 12; R 1,R 4,R 9,R 10和R 12独立地选自氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基, 6个取代的烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基; R 2,R 3,R 5和R 6独立地选自氢,C 1-6烷基, C 1-6烷氧基,苯氧基,C 1-8杂烷基,C 1-8杂烷氧基,取代的C 1-6烷基,C 3-8环烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,卤代,硝基 - ,氰基 - 羧基 - ,C 1-6羧基烷基和C 1-6烷基羰基; Ar是当式(I)中包括时形成多取代芳族烃或多元醇的部分 取代杂环基;(m),(r),(s),(t),(u)和(v)分别为0或1;(p)为零或正整数; 并且R11是基本上非抗原性的聚合物。当双前体药物的聚合物部分被切割并且之后在体内快速产生母体分子时,优选由1,6或1,4苄基消除 - 反应。 还公开了制备化合物的方法和治疗方法。
    • 4. 发明授权
    • Terminally-branched polymeric linkers and polymeric conjugates containing the same
    • 末端支化的聚合物接头和含有它们的聚合物共轭物
    • US06638499B2
    • 2003-10-28
    • US10067930
    • 2002-02-06
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • A61K31785
    • C07D491/22A61K47/60C07H15/252C08F283/00
    • The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4, Y1-2 are independently O, S or NR9; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2); R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroakoxy; (m1) and (m2) are independently zero or one; (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R1 is a polymeric residue. which is optionally capped with a moiety of the formula:
    • 本发明涉及下式的聚合物 - 前药转运形式:其中:E1-4独立地选自氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基,C 1-6取代的 烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基,C 1-6烷氧基,苯氧基,C 1-6杂烷氧基,E1-4中的至少一个包括B部分 其中B是离去基团,OH,含羟基或氨基的部分的残基或其中J 1与J相同,或者定义J和E5的基团的另一个成员与E1-4相同或另一个成员 定义E1-4的基团,Y1-2独立地为O,S或NR9; M为选自X或Q的杂原子; 其中X是吸电子基团,Q是含有从C(= Y2)定位为三至六个原子的自由电子对的部分; R2-5和R7-9独立地选自氢,C1-6烷基 ,C3-12支链烷基,C3-8环烷基,C1-6取代的烷基,C3-8取代的环烷基,芳基,取代的芳基,芳烷基,C1-6杂烷基,取代的C1-6杂烷基,C1-6烷氧基,苯氧基和C1 -6杂芳氧基;(m1)和(m2)分别为零或一;(n1),(n2),(p1),(p2)和(q)分别为零或正整数,Z为吸电子基团 ; 并且R 1是聚合物残基,其任选地被下式的部分封端:
    • 5. 发明授权
    • Terminally-branched polymeric linkers and polymeric conjugates containing the same
    • 末端支化的聚合物接头和含有它们的聚合物共轭物
    • US06395266B1
    • 2002-05-28
    • US09293624
    • 1999-04-16
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • A61K31785
    • C07D491/22A61K47/60C07H15/252C08F283/00
    • The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4; Y1-2 are independently O, S or NR9; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(=Y2); R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-16 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy; (m1) and (m2) are independently zero or one; (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R1 is a polymeric residue. which is optionally capped with a moiety of the formula:
    • 本发明涉及下式的聚合物 - 前药转运形式:其中:E1-4独立地选自氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基,C 1-6取代的 烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基,C 1-6烷氧基,苯氧基,C 1-6杂烷氧基,E1-4中的至少一个包括B部分 其中B是离去基团,OH,含羟基或氨基的部分的残基或其中J 1与J相同,或者定义J和E5的基团的另一个成员与E1-4相同或另一个成员 定义E1-4的基团; Y1-2独立地为O,S或NR9; M为选自X或Q的杂原子; 其中X是吸电子基团,Q是含有从C(= Y2)定位为三至六个原子的自由电子对的部分; R2-5和R7-9独立地选自氢,C1-6烷基 ,C3-12支链烷基,C3-8环烷基,C1-6取代烷基,C3-8取代环烷基,芳基,取代芳基,芳烷基,C1-16杂烷基,取代C1-6杂烷基,C1-6烷氧基,苯氧基和C1 -6杂烷氧基;(m1)和(m2)独立为零或一;(n1),(n2),(p1),(p2)和(q)独立为零或正整数,Z为吸电子基团 ; 并且R 1是聚合物残基,其任选地被下式的部分封端:
    • 7. 发明授权
    • Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
    • 含氨基的生物活性剂的三烷基锁定促进的聚合物前药
    • US06303569B1
    • 2001-10-16
    • US09137430
    • 1998-08-21
    • Richard B. GreenwaldYun H. ChoeAnnapurna Pendri
    • Richard B. GreenwaldYun H. ChoeAnnapurna Pendri
    • A61K31215
    • C07C237/22A61K47/60C07B2200/11C07C271/16C07C271/22
    • The present invention is directed to double prodrugs containing polymeric-based transport forms. These polymeric compounds comprise the formula: wherein: B is H, OH, OSiR13, a residue of an amine-containing target moiety or a residue of a hydroxyl-containing moiety; L1 and L2 are bifunctional linking moieties; Y2is O or S; R2 is selected from the group consisting of C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy; R9, R10, R13 are independently one of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3 S substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy; Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; (m) is zero or one; and R11 is a polymer residue. The first prodrug is generated when the polymeric portion of the double prodrug is cleaved and the parent molecule is generated rapidly thereafter in vivo, as a result of a trialkyl lock type lactonization-type reaction.
    • 本发明涉及含有基于聚合物的输送形式的双重前药。 这些聚合化合物包括下式:其中:B是H,OH,OSiR13,含胺目标部分的残基或含羟基部分的残基; L1和L2是双官能连接部分; Y 2是O或S; R 2 选自C1-6烷基,C3-12支链烷基,C3-8环烷基,C1-6取代烷基,C3-8取代环烷基,芳基,取代芳基,芳烷基,C1-6杂烷基,取代C1- 6个杂烷基,C 1-6烷氧基,苯氧基和C 1-6杂烷氧基; R 9,R 10,R 13独立地为氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基,C 1-6取代的烷基,C 3 S取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基,C 1-6烷氧基,苯氧基和C 1-6杂烷氧基; Ar是当式(I)中包括时, 取代的芳族烃或多取代的杂环基;(m)为0或1; 并且R11是聚合物残基。当双前体药物的聚合部分被切割并且其后在体内快速产生母体分子时,由于三烷基锁定型内酯化反应的结果产生第一种前体药物。